Skip to content
Subscriber Only

Pfizer Lipitor Sales Are Threatened by Ranbaxy Generic Copy

Pfizer Inc.’s $10.7 billion cholesterol pill Lipitor gained a rival today after Ranbaxy Laboratories Ltd. was cleared by U.S. regulators to sell copies of the drug.

Pfizer, the world’s biggest drugmaker, lost on another front when WellPoint Inc., the largest insurer by enrollment, said it will support use of a generic version by its members by assigning a lower co-pay to the copycat than to the brand drug.